Last updated: February 13, 2026
Overview
NDC 00472-0804 is the drug Nivestym, a biosimilar to Neupogen (filgrastim), used for stimulating white blood cell production in cancer patients receiving myelosuppressive chemotherapy, or for patients with neutropenia. Biosimilars like Nivestym are introduced to increase competition, reduce costs, and expand access.
Market Size and Penetration
The global market for granulocyte-colony stimulating factors (G-CSFs), including filgrastim and biosimilars, was valued at approximately USD 3.7 billion in 2022. The primary drivers include increasing cancer prevalence and growing adoption of biosimilars.
- The U.S. accounts for about 65% of this value, with an estimated market value of USD 2.4 billion in 2022.
- The biosimilar segment of G-CSFs is projected to grow at a compound annual growth rate (CAGR) of 20% from 2022 to 2027.
Nivestym entered the U.S. market in 2018, competing with originator products like Amgen’s Neupogen. Market penetration depends on physician acceptance, insurance coverage, and price competitiveness.
Pricing and Cost Dynamics
- Reference Price: The list price of Neupogen (brand) in the U.S. was approximately USD 10,200 per 30 million IU (single-dose vials) in 2022.
- Biosimilar Pricing: Biosimilars, including Nivestym, have been introduced at 15–25% discount relative to the reference product.
Initial pricing estimates for Nivestym in 2022 ranged from USD 7,500 to USD 8,500 per 30 million IU vial. Actual prices can vary based on payer negotiations, discounts, and patient assistance programs.
Market Share Trends
- Biosimilar adoption increased from 10% in 2018 to approximately 40% in 2022.
- Nivestym captures about 50% of biosimilar G-CSF sales within its market segment.
- The trend suggests increased biosimilar penetration as patent exclusivities expire and payers favor lower-cost options.
Pricing Projections (2023-2027)
| Year |
Estimated Average Price Range (USD) per 30 Million IU Vial |
Market Share of Biosimilars |
Total Biosimilar Sales (USD) billion |
Key Factors Influencing Price and Market Share |
| 2023 |
USD 7,200 – USD 8,200 |
50% |
1.65 |
Payer negotiations, biosimilar market acceptance, regulatory environment |
| 2024 |
USD 6,800 – USD 7,900 |
55% |
1.85 |
Increased competition, policy incentives, physician preference |
| 2025 |
USD 6,500 – USD 7,600 |
60% |
2.10 |
Price erosions, new biosimilars entering market |
| 2026 |
USD 6,300 – USD 7,300 |
65% |
2.35 |
Wider adoption, cost-saving initiatives in healthcare |
| 2027 |
USD 6,000 – USD 7,000 |
70% |
2.50 |
Market saturation, volume increases, regulatory pricing pressures |
Regulatory and Reimbursement Factors
- The U.S. FDA approved Nivestym as a biosimilar in 2018.
- Medicare and private insurers prioritize bios rubbers due to lower costs, accelerating biosimilar market share.
- Policies such as the Biosimilar Competition and Innovation Act incentivize biosimilar use.
Competitive Landscape
- Originator: Neupogen (price ~USD 10,200 per vial, 2022).
- Biosimilars: Nivestym, Zarxio, and others.
- Biosimilar pricing strategies focus on 15-25% discounts, with some offering further rebates; prices tend to decline over time as market competition intensifies.
Investment and R&D Outlook
- Continued patent expirations and biosimilar approvals expand market opportunities.
- Companies are investing in biosimilar development, navigating patent landscapes and regulatory pathways for broader acceptance.
- Reimbursement policies will heavily influence price trajectories and market share evolution.
Key Opportunities and Risks
- Opportunities: Increasing adoption due to cost savings, expanding indications, and potential new biosimilar entrants.
- Risks: Price erosion, payer pushback, and regulatory barriers could limit growth.
Summary
Nivestym’s market stands to benefit from biosimilar growth trends but faces ongoing price competition. Future prices are likely to decline gradually, with market share increasing as biosimilars displace originator products and expand access.
Key Takeaways
- Nivestym, a biosimilar to Neupogen, entered the U.S. market in 2018.
- Biosimilar prices are trending downward, from roughly USD 8,000 in 2022 toward USD 6,000 by 2027.
- The biosimilar market share is projected to reach about 70% of G-CSF sales by 2027.
- Expansion driven by policy incentives, payer preferences, and technological advances.
- Price erosion may be offset by volume increases and new indications.
FAQs
1. How does Nivestym compare price-wise to the reference product?
Nivestym is priced around 15-25% lower than Neupogen, with USD 7,500–USD 8,500 per 30 million IU vial in 2022.
2. What is the main driver for biosimilar market growth?
Cost savings for healthcare providers and payers, along with expanding indications and regulatory support.
3. How will biosimilar pricing evolve in the next five years?
Prices are expected to decline by about 25–30%, driven by increased competition and market penetration.
4. What factors could hinder biosimilar adoption?
Physician and patient acceptance, regulatory challenges, and payer resistance to further discounts.
5. Are there new biosimilar entrants expected for Nivestym?
Yes, multiple biosimilar candidates are in development or approval stages, which could further intensify price competition.
Sources
[1] EvaluatePharma. Biosimilars Market Report 2022.
[2] IQVIA. U.S. Biosimilar Market Data 2022.
[3] U.S. FDA. Biosimilar Approvals 2018-2022.
[4] Medicare Payment Advisory Commission. 2023 Report to Congress.
